Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large-cap value stocks. The market outlook is as uncertain as it gets. On January 18 ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed as inflation drops. In a fresh appearance on CNBC’s ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

Truist Financial lifted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th.